
CCSI Stock Forecast & Price Target
CCSI Analyst Ratings
Bulls say
Consensus Cloud Solns is benefiting from a successful shift away from legacy e-faxing toward a higher-value healthcare interoperability platform, with Corporate revenue growth rebounding to +4% y/y in 2Q:26 and Corporate growth at +9% y/y. Its fundamentals are strengthened by industry-leading margins, including an adjusted EBITDA margin of 52.9% and gross margin near 80%, alongside about $120M of annual free cash flow and an 18% FCF yield that supports continued deleveraging. Debt has fallen from about $792M after the 2021 spin-off to $548M in 2Q:26, cutting debt/EBITDA to 2.8x, while the VA mandate, 103% net revenue retention, and healthcare-focused acquisitions like Dock Health provide visible growth catalysts.
Bears say
Consensus Cloud Solns is vulnerable to intensifying competition from large technology firms, nimble smaller rivals, and new entrants, all of which could erode market share, weaken its land-and-expand strategy, and pressure customer retention. Its heavy debt load also limits flexibility to invest in growth, while a recession or macroeconomic instability could prompt hospitals and health systems to cut back on nonessential health-tech spending, hurting demand and making its ROI-driven value proposition less compelling. In addition, because the business handles highly sensitive personal information, any security breach could cause serious reputational damage, and the limited trading history adds further uncertainty.
This aggregate rating is based on analysts' research of Consensus Cloud Solutions and is not a guaranteed prediction by Public.com or investment advice.
CCSI Analyst Forecast & Price Prediction
Start investing in CCSI
Order type
Buy in
Order amount
Est. shares
0 shares